DIRS.INFO The most relevant business & tech news

☆ Jimmy Kimmel Isn’t Expecting an Apology From Aaron Rodgers
▼ + stars: | 2024-01-09 | by ( Trish Bendix | ) www.nytimes.com time to read: +2 min

Kimmel cited Rodgers’ “Thanksgiving Day Parade-sized ego” as part of the problem and said he wasn’t expecting an apology, but he did want to differentiate between the jokes made on “Jimmy Kimmel Live” and flat-out lies. I apologize for it, which is what Aaron Rodgers should do, which is what a decent person would do. I’ll accept his apology and move on.” — JIMMY KIMMEL“But here’s the thing: I spent years doing sports. Aaron Rodgers has a very high opinion of himself. The idea that his brain is just average is unfathomable to him.” — JIMMY KIMMEL“We learned during Covid somehow he knows more about science than scientists.

Persons: Kimmel, Rodgers ’, wasn’t, Jimmy Kimmel, Donald Trump, Aaron Rodgers, ” — JIMMY KIMMEL, I’ve, God, ” — JIMMY KIMMEL “, Covid, — JIMMY KIMMEL “ Aaron, Aaron, ’, JIMMY KIMMEL “ Organizations: Cal

☆ Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
▼ + stars: | 2023-12-25 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +10 min

Lilly's Zepbound recently entered the weight loss market, and is off to a strong start. But what's ahead for the weight loss trade in 2024? Beyond weight loss One of 2023's most pivotal events in the space was Novo Nordisk's release of top line results from its Select trial in August . In 2023, the exuberance around weight loss drugs roiled markets in many unexpected ways. The affected companies have also been very vocal in addressing how they plan to coexist with these weight loss products.

Persons: Oprah Winfrey, Eli Lilly, they've, Lilly's, Lilly's Zepbound, Andy Acker, Janus Henderson's, Lilly, Novo, FactSet, Acker, Janus, Buzz, Gregory Renza, Renza, Goldman Sachs, Chris Shibutani, Mike Kratky, Kratky, Dexcom, Leerink, Winfrey, I've, Winfrey's, Michael Bloom Organizations: Novo Nordisk, Wall Street, Wall, RBC Capital, Pfizer, Structure Therapeutics, AstraZeneca, Leerink, Nestle, Oprah Daily, Winfrey, International Locations: Friday's, Eccogene, MedTech, 3Q23

☆ Sanofi CEO under pressure to woo investors after spending shock
▼ + stars: | 2023-12-05 | by ( Ludwig Burger | ) www.reuters.com time to read: +5 min

[1/2] Paul Hudson, chief executive officer of Sanofi, speaks during the annual results news conference at the company's headquarters in Paris, France, February 4, 2022. The market's shock reaction, compounded by a lack of details of the spending push, overshadowed Sanofi's plan to list its consumer unit, in line with an industry trend. David Song, a portfolio manager and investment partner at Tema ETF, said: "The narrative of Sanofi has been a margin expansion, earnings-driven story for a lot of investors." "Shouldn't investors give credit to managements who care about long-term shareholder value creation?," said Song. ($1 = 0.9206 euros)Reporting by Ludwig Burger; Editing by Josephine Mason and Emelia Sithole-MatariseOur Standards: The Thomson Reuters Trust Principles.

Persons: Paul Hudson, Sanofi, Benoit Tessier, Hudson, Dan Lyons, Janus Henderson, Markus Manns, David Song, Fabian Wenner, Julius Baer, Union's Manns, Janus Henderson's Lyons, Johnson, Song, Ludwig Burger, Josephine Mason, Emelia Organizations: REUTERS, Reuters, Janus Henderson Investors, Germany's Union Investment, Tema, Thomson Locations: Paris, France, British, Hudson, Denver, Swiss, Tema

☆ Novartis lifts sales growth target to 5% per year through 2027
▼ + stars: | 2023-11-28 | by ( Ludwig Burger | ) www.reuters.com time to read: +1 min

The logo of Swiss drugmaker Novartis is pictured at the company's French headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS/Charles Platiau/File Photo Acquire Licensing RightsCompanies Novartis AG FollowSandoz GmbH FollowFRANKFURT, Nov 28 (Reuters) - Novartis (NOVN.S) has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after it sold off its generic-drugs business. The medium-term target, which excludes any foreign exchange effects, is mainly driven by six drugs, led by Kisqali, it said in a presentation on Tuesday. The sales forecast, up from a previous revenue growth target of 4% through 2027, is also underpinned by demand for Pluvicto, a precision radiotherapy against prostate cancer, and self-administered multiple sclerosis (MS) shot Kesimpta. Reporting by Ludwig Burger; Editing by Miranda Murray and Miral FahmyOur Standards: The Thomson Reuters Trust Principles.

Persons: Charles Platiau, Kisqali, Vas, Kesimpta, drugmaker, Sandoz, Ludwig Burger, Miranda Murray, Miral Organizations: Swiss, Novartis, REUTERS, Companies Novartis, Sandoz, FRANKFURT, Thomson Locations: Rueil, Malmaison, Paris, France, Basel, Swiss

☆ To Wear the Sudoku Crown, One Must Solve Any Number of Puzzles
▼ + stars: | 2023-11-03 | by ( Siobhan Roberts | Chloë Ellingson | ) www.nytimes.com time to read: +2 min

On a mid-October Monday, shortly before 9 a.m., 179 elite puzzlers made their way into the ballroom of a Toronto hotel and found their allocated seats for the World Sudoku and Puzzle Championships. Quiet descended as proctors distributed booklets for Round 1: nine Sudoku puzzles, with a 45-minute time limit. He is a three-time world Sudoku champion, and in 2018 he won the title of world puzzle champion, making him the first person to win both honors. The annual championship event comprises two days of Sudoku, followed by three days of other types of pencil-and-paper logic puzzles. There were also trickier variants, such as “Difference Sudoku,” for which the standard rules apply, but also each number shown in a circle between two adjacent cells indicates the difference of the numbers in those two cells.

Persons: puzzlers, Valentin Miakinen, Hwangrae Lee, Thomas Snyder, “, Snyder, ”, Laura Tarchetti, Toni Borozan, Jouni Sarkijarvi Organizations: San Francisco Bay Area Locations: Toronto, France, Korea, San Francisco Bay, revel, Croatia, Finland

☆ Stifel says this under-the-radar biotech stock can still rally more than 50% from here
▼ + stars: | 2023-11-02 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +1 min

It's not too late for investors to ride along with MoonLake Immunotherapeutics despite the Swiss biotech having more than quadrupled in price this year, according to Stifel. Shares of MoonLake have soared 354% in 2023, but Stifel believes more gains lay ahead. MLTX YTD mountain MLTX YTD chart Analyst Alex Thompson believes MoonLake's sonelokimab drug, which targets diseases in dermatology and rheumatology, could eventually achieve $4.2 billion in U.S. revenue. The next trial readout for the drug is in psoriatic arthritis, with data expected in early November. "We view recent acquisitions in the TYK2 and TL1A space ($4-11B) as supportive of Strategics' interest/willingness to pay premiums in these markets," Stifel noted.

Persons: It's, MoonLake Immunotherapeutics, Stifel, Alex Thompson, we've, Thompson, MoonLake, — CNBC's Michael Bloom

☆ Stress rash: What to do when stress gives you hives
▼ + stars: | 2023-11-01 | by ( Taylor Nicioli | ) edition.cnn.com time to read: +5 min

What causes a stress rash? Stress hives can occur in response to elevated body temperatures caused by stress. What does a stress rash look like? Stress rashes are occasionally paired with swelling of the eyelids or the lips, Ploch said. How to get rid of a stress rashThe best treatment for a stress rash is to prevent it altogether, but don’t panic if after a hard day at work your skin begins to itch.

Persons: ‘, ’ ”, Whitney, dermatopathology, Lauren Ploch, Ploch, “, ” Ploch Organizations: CNN, Health, University of Colorado School of Medicine, American Academy of Dermatology Association, Scripps Health, American College of Allergy, Asthma, Immunology, World Health Organization Locations: Augusta , Georgia

☆ AstraZeneca to invest $245 mln in Cellectis to boost gene therapy prospects
▼ + stars: | 2023-11-01 | by ( ) www.reuters.com time to read: +1 min

The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. Cellectis' gene-editing technology and manufacturing capabilities to design novel cell and gene therapy products will help strengthen AstraZeneca's growing offering in the space, it said. AstraZeneca said that as part of the deal, it will pay Cellectis $105 million by the end of this year. That includes an $80 million equity investment, which will be followed by another $140 million in early 2024, which will give AstraZeneca a stake of about 44% in the French company. The Anglo-Swedish pharma company said it had exclusive rights to 25 genetic targets, of which up to 10 candidate products could be explored for development.

Persons: Rachel Wisniewski, Aby Jose Koilparambil, Savio D'Souza Organizations: AstraZeneca, REUTERS, Swedish pharma, Thomson Locations: North America, Wilmington , Delaware, U.S, Swedish, Bengaluru

☆ Here are Monday's biggest analyst calls: Nvidia, Tesla, Apple, AbbVie, Chevron, Krispy Kreme, Roku and more
▼ + stars: | 2023-10-30 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Here are the biggest calls on Wall Street on Monday: JPMorgan upgrades Eastman Chemical to overweight from neutral JPMorgan said it sees an earnings rebound for Eastman Chemical. Bank of America reiterates Roku Bank of America said it's standing by its buy rating heading into earnings later this week. JPMorgan downgrades Olin to neutral from overweight JPMorgan downgraded the chemical company citing concerns about reduced product demand. " JPMorgan downgrades Valley National to neutral from overweight JPMorgan downgraded the regional bank mainly on valuation. Bank of America initiates Cooper Companies as buy Bank of America said the contact lens company is well positioned. "

Persons: Bernstein, Tesla, underperform Bernstein, Morgan Stanley, Apple, it's, Pinterest, Raymond James downgrades, Raymond James, TD Cowen, Decker, Baird downgrades Datadog, Baird, JPMorgan downgrades Newell, JPMorgan downgrades Olin, Olin, Harris, Hess, Truist, Piper Sandler, Piper, Oppenheimer, Goldman Sachs, Okta, Goldman, Wolfe Organizations: JPMorgan, Eastman Chemical, Barclays, Bank of America, Roku Bank of America, Apple, Citi, Raymond James downgrades Cisco, Cisco, Stanley Black, JPMorgan downgrades, JPMorgan downgrades Newell Brands, Newell Brands, UBS, East West Bancorp, Chevron, of America, Cooper Companies, Microsoft, MSFT, Deutsche Bank, Nvidia, Deutsche, Broadcom Locations: China, Okta

☆ Sanofi loses $21 bln in market value after dropping 2025 profit target
▼ + stars: | 2023-10-27 | by ( Ludwig Burger | ) www.reuters.com time to read: +6 min

Under a push to spend more on immunology and inflammation drug development, the company abandoned a target for a 32% operating profit margin for 2025 to focus on "long-term profitability". EPS would see a strong rebound in 2025 but not enough to sustain the previous margin target. CONSUMER STAND-ALONECEO Hudson said the core innovative drugs business had improved enough to soon do without the more predictable cash flows from consumer products. The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon, France, September 30, 2023. The timing of the potential consumer listing, which Sanofi said would be in the fourth quarter of 2024 or later, would be set to maximize shareholder value.

Persons: Hudson, Sanofi, drugmaker, Paul Hudson, Terence McManus, Johnson, we've, Gonzalo Fuentes, Roche, Dupixent, Ludwig Burger, Sherry Jacob, Phillips, Mark Potter, Sharon Singleton Organizations: Sanofi, Bellevue Asset Management, Reuters, Barclays, Johnson, GSK, Pfizer, Bayer, Polyclonals, REUTERS, Provention, Merck & Co, Thomson Locations: France, Bellevue, Lyon, Paris

The logo for AbbVie is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, New York, U.S., November 17, 2021. Morningstar analyst Damien Conover said he had already factored in a hit to Imbruvica from the Medicare price negotiations, so the update on impairment was not "overly significant to our view." Humira's global third-quarter sales fell 36% to $3.55 billion, but topped analysts' estimates of $3.48 billion, according to LSEG data. AbbVie in July trimmed its 2023 view for Humira sales erosion to 35%, from 37% earlier. The company's newer immunology drugs Skyrizi and Rinvoq generated sales of $2.13 billion and $1.11 billion, respectively, ahead of analyst expectations of $2.10 billion and $1.02 billion.

Persons: Andrew Kelly, girding, AbbVie, Imbruvica, Morningstar, Damien Conover, Humira, Piper Sandler, Christopher Raymond, Ingelheim, Leroy Leo, Christy Santhosh, Maju Samuel, Bill Berkrot Organizations: New York Stock Exchange, REUTERS, U.S, Medicare, Analysts, Sandoz, AbbVie, Thomson Locations: New York City , New York, U.S, The Illinois, Bengaluru

☆ Sanofi loses $21 billion in market value after dropping 2025 profit target
▼ + stars: | 2023-10-27 | by ( ) www.cnbc.com time to read: +2 min

Chesnot | Getty ImagesSanofi stock plunged on Friday, wiping 20 billion euros ($21 billion) off its market value, after it abandoned its 2025 profit target under a plan to list its consumer healthcare business to focus on its core innovative drugs business. Under a push to spend more on immunology and inflammation drug development, the company abandoned a target for a 32% operating profit margin for 2025 to focus on "long-term profitability." Sanofi shares trade at a 12 month forward price-to-earnings ratio of 11, a discount to AstraZeneca's 16 and global pharma index of 17, according to LSEG data. Bayer, led by a new CEO since June, has faced calls by several investors to split off its consumer business. EPS would see a strong rebound in 2025 but not enough to sustain the previous margin target.

Persons: Sanofi, drugmaker, Paul Hudson, Terence McManus, Kenvue, Johnson, Bayer Organizations: Chesnot, Getty, Sanofi, Bellevue Asset Management, Reuters, Barclays, Johnson, GSK, Pfizer Locations: Gentilly, Paris, France, Bellevue

☆ Eli Lilly is on a buying spree. Here’s what it means for investors like us
▼ + stars: | 2023-10-05 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +9 min

Still, he said it's "healthy" for a company like Eli Lilly — valued over $500 billion, as of Thursday — to be executing smaller deals. "They can still put their mark on an asset or a constellation of drugs," said Seigerman, who has a buy rating and $633-per-share price target on Eli Lilly stock. LLY 1Y mountain Eli Lilly's stock performance over the past 12 months. Details on the deals The three companies Eli Lilly bought this summer have drugs in various stages of the clinical development process. In the near term, though, they may result in a noisy third-quarter earnings report as Eli Lilly records the acquisitions.

Persons: Eli Lilly, Mounjaro, Jim Cramer, Eli Lilly's, Lilly, –, Verzenio, Evan Seigerman, Eli Lilly —, Seigerman, Lilly's, Dice, Versanis, Sigilon, that's, BMO's Seigerman, Eli, we'd, Jim Cramer's, Jim, Daniel Acker Organizations: Indianapolis, U.S . Food, Drug Administration, BMO Capital, Immunology, Therapeutics, Siligon Therapeutics, Oncology, Club, Department of Health, Human Services, Dice Therapeutics, Alzheimer's, Treasury, CNBC, Bloomberg, Getty

☆ Eli Lilly appoints new obesity unit head ahead of key Mounjaro decision
▼ + stars: | 2023-10-04 | by ( Reuters Staff | ) www.reuters.com time to read: +1 min

(Reuters) -Eli Lilly and Co on Wednesday appointed a new chief for its diabetes and obesity unit in a string of leadership changes ahead of a key regulatory decision on the use of its potential blockbuster drug Mounjaro as a weight-loss treatment. Slideshow ( 2 images )Mounjaro, chemically known as tirzepatide, is already being prescribed by doctors off-label as an obesity treatment. In his new role, Jonsson will oversee Lilly’s launched products and late-stage development of diabetes and obesity treatments, including tirzepatide and other candidates such as its next-generation obesity drug retatrutide and obesity pill orforglipron. Mason, who has also spent more than three decades with Lilly, oversaw the late-stage development and the launch of Mounjaro. The diabetes drug, which clocked in sales of $979.7 million in the latest quarter, belongs to a class of drugs known as GLP-1s that stimulate insulin production.

Persons: Eli Lilly, Patrik Jonsson, Lilly USA, Mike Mason, Jonsson, Lilly’s, Mason, Lilly, Daniel Skovronsky Organizations: Reuters Locations: Sweden, Scandinavia, Italy, Japan, Jonsson

☆ Evercore ISI says this biotech stock is a high risk, high reward play, with more than 200% upside
▼ + stars: | 2023-10-03 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +2 min

Evercore ISI initiated coverage of Aclaris Therapeutics , a clinical stage biotech working on immunology and inflammation drugs, at an outperform, saying the market is underpricing its odds for success heading into the release of clinical trial data. Admittedly, the upcoming trial results may not be successful, which makes the bet a risky one, he said. If Aclaris is successful with zunsemetinib, it will be the only MK2 inhibitor on the market for rheumatoid arthritis, which Evercore ISI sees as an advantage. A similar drug from Bristol Myers Squibb wasn't successful in a different form of arthritis. Evercore ISI expects investors are only pricing in a 20% chance of positive data from the clinical trial, whereas the firm expects the odds are closer to 50%.

Persons: Gavin Clark, Clark, Gartner, zunsemetinib, Aclaris, Bristol Myers Squibb wasn't, — CNBC's Michael Bloom Organizations: Evercore ISI, Aclaris Therapeutics, Gartner, Clark, Bristol Myers Squibb

☆ Here are Tuesday's biggest analyst calls: Nvidia, Rivian, Amazon, Airbnb, Warby Parker, HP, FedEx and more
▼ + stars: | 2023-10-03 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Here are Tuesday's biggest calls on Wall Street: KeyBanc reiterates Nvidia as overweight KeyBanc raised its price target on Nvidia to $750 per share from $670 and said it sees "outsized growth." Bank of America adds FedEx to the US1 list Bank of America added the stock to its top picks list. "Upgrading Clean Energy Fuels (CLNE) from Outperform to Strong Buy, with the company on the cusp of ramping up in-house RNG production." JPMorgan reiterates Amazon as a top pick JPMorgan said ignore the noise and buy the dip in shares of Amazon. Bank of America initiates Dycom as buy Bank of America said in its initiation of the telecommunications infrastructure company that it's uniquely positioned.

Persons: KeyBanc, Ally, Evercore, bode, Stifel, Churchill, CHDN, Raymond James, Baird, Vestis, Piper Sandler, Tesla, IBKR, Morgan Stanley, Rivian, it's, Warby Parker, Booz Allen Hamilton, Goldman Sachs, Wedbush Organizations: Nvidia, Aclaris Therapeutics, ISI, Citi, Arista Networks, Arista, " Bank of America, FedEx, Bank of America, FedEx Corp, Owl Capital, Swift Transportation, Evercore ISI, TAM, Energy Fuels, JPMorgan, FTC, DOJ, HP Inc, underperform Bank of America, HPQ, UBS, Booz, of America, Emerson Electric, Warner Music Group, Apple, Constellation Brands Locations: China, CY23

And I told her that many, many scientists work very, very hard," Kariko added. BioNTech said in June that about 1.5 billion people across the world had received its mRNA shot, co-developed with Pfizer (PFE.N). [1/11]Katalin Kariko and Drew Weissman win the 2023 Nobel Prize in Physiology or Medicine at the Karolinska Institute in Stockholm, Sweden October 2, 2023. The medicine prize kicks off this year's Nobel awards with the remaining five to be unveiled in coming days. The prizes, first handed out in 1901, were created by Swedish dynamite inventor and wealthy businessman Alfred Nobel.

Persons: Weissman, Katalin Kariko, Drew Weissman, Kariko, BioNTech, Rickard Sandberg, Susan Francia, immunologist, ”, Sir Andrew Pollard, Alfred Nobel, Swede Svante Paabo, Alexander Fleming, Karl Landsteiner, Niklas Pollard, Johan Ahlander, Ludwig Burger, Terje Solsvik, Andrew Cawthorne Organizations: Medicine, Nobel, Sweden's Karolinska Institute, University of Szeged, University of Pennsylvania, Pfizer, Karolinska Institute, TT News Agency, REUTERS Acquire, Boston University, Oxford University, AstraZeneca, Moderna, Thomson Locations: STOCKHOLM, COVID, Hungary, Pennsylvania, Szeged, U.S, Stockholm, Sweden, Frankfurt, Krisztina, Budapest, Oslo

☆ mRNA vaccine: 5 things to know
▼ + stars: | 2023-10-02 | by ( Katie Hunt | ) edition.cnn.com time to read: +5 min

Here are five things to know about Karikó and Weissman’s game-changing research and mRNA vaccines. What mRNA doesMessenger RNA, or mRNA, is a form of nucleic acid that tells cells what to do based on the information contained in DNA. Messenger RNA-based vaccine technology doesn’t rely on a modified version of a virus to produce an immune response. Potential beyond fighting Covid-19The advent of mRNA vaccine technology has led to safe and strong protection against Covid-19. And mRNA technology is also being checked out as a possible alternative to gene therapy for intractable conditions such as sickle cell disease.

Persons: Katalin Karikó, Drew Weissman, Peggy Peterson, Robin Shattock, ” Shattock, —, Karikó, Weissman, ”, Roberts, Thomas Perlmann, it’s Organizations: CNN, University of Pennsylvania, Penn Medicine, Imperial College London, Covid, Penn’s Perelman, of Medicine, Vaccine, Perelman School of Medicine, Nobel Assembly Locations: Hungary

☆ Here are Friday's biggest analyst calls of the day: Tesla, Ford, Apple, Amazon, Disney, Nike, FedEx and more
▼ + stars: | 2023-09-29 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Bank of America reiterates Disney as buy Bank of America said it's standing by its buy rating on the stock. Morgan Stanley reiterates Ford as overweight Morgan Stanley said it's standing by its overweight rating on shares of Ford despite the United Auto Workers strike. Canaccord reiterates Tesla as buy Canaccord said its standing by its buy rating on Tesla ahead of its upcoming delivery numbers report. Morgan Stanley reiterates Apple as overweight Morgan Stanley said it's standing by its overweight rating on shares of Apple. Morgan Stanley reiterates Amazon as overweight Morgan Stanley said Amazon continues to be the "dominant" player in e-commerce.

Persons: Jefferies, Edward Jones downgrades Berkshire Hathaway, Edward Jones, Morgan Stanley, Ford, it's, Canaccord, Tesla, we've, Goldman Sachs, Raymond James, Bud Light, Apple, Amazon, Brinker, Stifel, Huntington Organizations: Jefferies, Ball Corporation, Bank of America, Disney, DIS, CYE23, Texas, 3Q23, Brands, Burger King, Ford, United Auto Workers, HSBC, FedEx, UPS, DHL, Nike, Immunology, " Bank of America, Anheuser, Busch InBev, of America, Apple, Citi Locations: Texas, QSR, North America, Asia, ZION

☆ Artificially sweetened ultraprocessed foods linked to depression in women, study finds
▼ + stars: | 2023-09-20 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +7 min

CNN —Eating greater amounts of ultraprocessed food and drinks, especially if those items are artificially sweetened, may be linked to the development of depression, according to a new study. Ultraprocessed foods include hot dogs, sausages, French fries, sodas, store-bought cookies, cakes, candies, ice cream and many foods containing artificial sweeteners. For one, there is a known link between ultraprocessed foods and chronic inflammation, Chan said. For example, studies have linked ultraprocessed foods colorectal cancer in men and heart disease and early death in both men and women. In addition, the study is observational, which means that researchers can only find an association between the onset of depression and the intake of ultraprocessed foods.

Persons: ” Gunter Kuhnle, ”, Andrew T Chan, Daniel K, Harvard T.H, Chan, Kuhnle, ” Marion Nestle, Paulette Goddard, ” Chan, David Katz, ” Katz, ” It’s, Katz, It’s, Paul Keedwell, Keith Frayn, Frayn, ” Frayn Organizations: CNN, University of Reading, Harvard Medical School, Harvard, of Public Health, Massachusetts General Hospital, New York University, ” Association, JAMA, Nurses, True Health Initiative, Royal College of Psychiatrists, BMI, University of Oxford Locations: Chan, Boston, Massachusetts, McDonald’s

☆ A Decongestant in Many Cold Medicines Is Ineffective
▼ + stars: | 2023-09-12 | by ( Dani Blum | More About Dani Blum | ) www.nytimes.com time to read: +2 min

Pseudoephedrine, which is found in behind-the-counter products like Sudafed, is effective at clearing congestion, Dr. Dykewicz said; just keep in mind that it can come with side effects. After that, you run the risk of rebound congestion: when the mucosal surfaces in your nose swell, making you feel even more clogged up than before. There are some sprays that you can use for longer stretches, without the rebound risk, namely steroid sprays that contain ingredients like fluticasone (Flonase) or triamcinolone (Nasacort), which are available over-the-counter. Can I treat congestion without medication? In many cases, you can treat a stuffed-up nose by standing in a steamy shower or using a humidifier to help clear your nasal passages, Dr.

Persons: ”, Jennifer Le, Dykewicz, Allegra, Mark Aronica, Le, Andrew Lane, Johns Organizations: Skaggs School of Pharmacy, Pharmaceutical Sciences, University of California, Cleveland Clinic, Sinus Locations: San Diego

☆ Opinion: How Covid-19 is resurfacing after months of calm
▼ + stars: | 2023-09-05 | by ( Kent Sepkowitz | ) edition.cnn.com time to read: +6 min

Kent Sepkowitz CNNThere are several plausible reasons why this latest bump is occurring now after months and months of calm. To sort it out, I decided to perform an at-home rapid antigen test. One negative test on the first day of symptoms, especially with the rapid antigen test, is not determinative. The virus that causes Covid-19 infection is a simple scrap of RNA that cannot survive without a living cell to support it. This won’t be the last alarm, real or false, for me (and others) in the months ahead.

Persons: Kent Sepkowitz, Covid, —, overconfidence Organizations: Memorial Sloan Kettering Cancer Center, CNN, Kent Sepkowitz CNN, US, Twitter Locations: New York, United States, XBB

☆ Is It Time to Wear a Mask Again?
▼ + stars: | 2023-08-29 | by ( Dani Blum | More About Dani Blum | ) www.nytimes.com time to read: +1 min

As new Covid variants gain traction, reinfections become more common and cases climb in certain areas, a few schools and businesses are reinstating mask requirements. Here’s a refresher on where, when and how to mask. When should you wear a mask inside? Everyone’s risk tolerance varies, Dr. William Schaffner, an infectious disease specialist at the Vanderbilt University School of Medicine, said. “Certainly every time you add another person to the room, particularly people who are within three to five feet of you, that increases your chance of getting infected, exponentially,” Dr. Pekosz added.

Persons: reinfections, ”, Andrew Pekosz, William Schaffner, Pekosz Organizations: Johns Hopkins University Bloomberg School of Public Health, Vanderbilt University School of Medicine

☆ Women and doctors challenge taboos on dangers of HPV in Egypt
▼ + stars: | 2023-08-25 | by ( Nadeen Ebrahim | ) edition.cnn.com time to read: +8 min

The woman spoke to CNN on condition of anonymity, fearing ostracization from her community where the subject of sexually transmitted infections remains taboo. Cervical cancer is the fourth most common type of cancer among women globally, says WHO, and in 2020 it killed some 342,000 women globally. The ministry has also advised women to take the HPV vaccine. The HPV vaccine costs between 800 EGP ($25.9) to 1,000 EGP ($32) per dose. Other Middle Eastern countries have added the HPV vaccine to their national immunization programs, including Saudi Arabia, the United Arab Emirates and Libya.

Persons: CNN —, ”, ostracization, Lobna Darwish, Egypt’s, they’ve, “, Ola Arafa, Rafik Barakat, Arafa, ” Arafa, Barakat, ” Darwish, Nisreen Salah Omar Organizations: CNN, World Health Organization, WHO, World Bank, Egyptian, Personal Rights, Manchester, University of Mansoura, United Arab, Representatives, Mansoura University Locations: Egypt, Cairo, Mansoura, ”, Saudi Arabia, United Arab Emirates, Libya

☆ A biotech hedge fund that counts Yale’s endowment among its clients bought a new stake in this genetic testing company
▼ + stars: | 2023-08-16 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

Founded by brothers Julian and Felix Baker in 2000, the health care hedge fund focuses on biotech and life sciences investing. The biotech stock with a focus on neuroscience has surged more than 84% this year. Baker Bros. doubled down on its bet in Kymera Therapeutics , which it raised by more than 51%. The hedge fund also took new stakes in ImmunoGen , which has more than tripled this year, soaring 216%, and Day One Biopharmaceuticals , which is down by 34%. The hedge fund lowered its exposure to the biotech company, which develops treatments for cancer, by 5%.

Persons: Baker, Tisch, Julian, Felix Baker, Seagen, Yun Li Organizations: Baker Bros, Advisors, Yale, Acadia Pharmaceuticals, Kymera Therapeutics Locations: InVitae, Invitae, Acadia, ImmunoGen

Search resuls for: "Immunology"

25 mentions found